This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
stage distribution for screen-detected and non-screen-detected breast cancer cases for African American women; ER positivity for African American women; the transition probabilities across stages; the dwell time (time in one stage until progression to the next stage); the sensitivity and specificity of mammography; the use of mammography after patient reminders or lay health worker interventions; the distribution of local treatment for African American women diagnosed with breast cancer (breast conservation, breast conservation plus radiation, mastectomy); systemic treatment distribution (chemotherapy, tamoxifen, both, neither); and survival.
Study designs and other criteria for inclusion in the review
It was not stated whether a systematic review of the literature was undertaken. Limited information on the designs of the primary studies was provided. Some data were derived from population-level studies and US statistics and databases. In particular, SEER data from 1975 to 1979 were used to approximate the stage distributions of events for unscreened women, while data from the Breast Cancer Surveillance Consortium were used to represent the stage distribution for screen-detected African American women.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Thirty-five primary studies provided the published evidence.
Methods of combining primary studies
The primary studies appear to have been combined using a narrative method.
Investigation of differences between primary studies
Results of the review
The rate of ER positivity for African American women was 48% (range: 42.8 -53.2) in the age class 35 -49 years, 66% (range: 61.1 -70.9) in the age class 50 -64 years, and 76% (range: 71.5 -81.5) in the age class 65 -79 years.
The transition probabilities were 0.714 from ductal carcinoma in-situ (DCIS) to DCIS, 0.286 from DCIS to local cancer (Loc), 0.828 from Loc to Loc, 0.172 from Loc to regional cancer (Reg), 0.916 from Reg to Reg, 0.084 from Reg to distant cancer (Dist), and 0.99 from Dist to Dist.
The dwell time was 2.1 years for women of 59 years or younger, 3 years for women aged 60 to 69 years, and 4.7 years in women of 70 years and older.
During the first screen, the sensitivity of mammography was 93.6% for women aged 50 to 59 years, 94.1% for women aged 60 to 69 years, and 91.2% for women of 70 years and older. The specificity of mammography was 92.9% (age 50 -59 years), 92.6% (age 60 -69 years) and 93.4% (age 70 years and older), respectively.
During subsequent screens, the sensitivity of mammography was 76.5% for women younger than 50 years of age, and 73.8% for women older than 50 years of age. The specificity of mammography was 98.1% (women younger than 50 years) and 98.2% (women older than 50 years), respectively.
The median rate of African American women reporting mammograms in the past 2 years was 76.1% (range: 44.3 -85.5). The relative risk of being unscreened was 0.73 (range: 0.68 -0.92) after patient remainder interventions and 0.82 (range: 0.75 -0.89) after exposure to lay health worker interventions.
The other rates used in the model will not be reported here.
Methods used to derive estimates of effectiveness
The authors made some assumptions that were used in the decision model.
Estimates of effectiveness and key assumptions
The differences in distribution of ER status by race represented a proxy for general race-specific differences in tumour makers. Lobular and ductal in-situ cancers had the same natural history and survival. The interventions had an effect that persisted over the long term. Women diagnosed with DCIS were destined to progress to local stage-invasive disease, while those diagnosed with local stage who survived for 15 years without recurrence would have similar survival after that time as their age-and race-matched non-breast cancer cohort. Survival was the same for women with screen-detected and clinically-detected cancers.
Measure of benefits used in the economic analysis
The summary benefit measure used was the life expectancy associated with status quo screening and treatment (versus no screening), with lay health worker or patient remainder interventions (versus status quo), and enhanced treatment (versus status quo). The estimated benefits were discounted at an annual rate of 3%. Other model outputs, such as the number of mammograms and the number of false positives, were also reported.
Direct costs
An annual discount rate of 3% was used because of the long time period considered in the model. The unit costs were not presented separately from the quantities of resources used for all items. The health services included in the economic evaluation were mammography, treatment, patient time, tamoxifen, adjuvant chemotherapy, and interventions to enhance screening (reminder letter and lay health worker). Patient time covered the time for receiving screening, the diagnostic evaluation and treatment, and the travel and waiting time for receiving care. The cost/resource boundary of the health care system and the patient appears to have been adopted. The costs were estimated from multiple sources, such as Medicare reimbursement rates, prior studies, wholesale average prices, and the median US wage rates for African American women (for patient time). The source of the resource use was generally unclear. The exception being patient time data, which were based on published evidence. All of the costs were inflated to 2000 values using the medical care component of the Consumer Price Index.
